Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Aug 27;109(37):14767-14772. doi: 10.1073/pnas.1209721109

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

PMC Copyright notice

Fig. 3. — In vivo targeting of tumors by CMP hybridization with MMP-digested collagens. (A) In vivo NIRF images of mice bearing PC-3 prostate tumors at forward right and left flanks (circled) administered with 3.7 nmol of UV-activated IR-Ahx-^NB(GPO)₉ or sequence-scrambled control peptide, via tail vein injection. Ventral views of both mice at 96 h post-injection (PI), and after midline surgical laparotomy (open chest) indicate tumor specific and stable accumulation of only the IR-Ahx-(GPO)₉ and not the control peptide. (B) NIRF images of another pair of mice bearing PC-3 tumors at the same location at 102 h after IR-CMP injection and 24 h after MMPSense680 injection, showing colocalization (in yellow) of MMP activity (red) and CMP binding (green) in the tumors (circled) and knee joint (arrowhead). (C) Epifluorescence micrographs of the unfixed PC-3 tumor sections from (B), additionally stained in vitro with anti-Col 2 ¾C_short csc antibody (green) and anti-CD31-PE antibody conjugate (red). IR-Ahx-(GPO)₉ (blue) colocalized partially with anti-Col 2 ¾C_short antibody (green) particularly within the peri-vasculatures. No such colocalization was detected for the control peptide (Scale bars: 100 μm).

Inline graphic — In vivo targeting of tumors by CMP hybridization with MMP-digested collagens. (A) In vivo NIRF images of mice bearing PC-3 prostate tumors at forward right and left flanks (circled) administered with 3.7 nmol of UV-activated IR-Ahx-^NB(GPO)₉ or sequence-scrambled control peptide, via tail vein injection. Ventral views of both mice at 96 h post-injection (PI), and after midline surgical laparotomy (open chest) indicate tumor specific and stable accumulation of only the IR-Ahx-(GPO)₉ and not the control peptide. (B) NIRF images of another pair of mice bearing PC-3 tumors at the same location at 102 h after IR-CMP injection and 24 h after MMPSense680 injection, showing colocalization (in yellow) of MMP activity (red) and CMP binding (green) in the tumors (circled) and knee joint (arrowhead). (C) Epifluorescence micrographs of the unfixed PC-3 tumor sections from (B), additionally stained in vitro with anti-Col 2 ¾C_short csc antibody (green) and anti-CD31-PE antibody conjugate (red). IR-Ahx-(GPO)₉ (blue) colocalized partially with anti-Col 2 ¾C_short antibody (green) particularly within the peri-vasculatures. No such colocalization was detected for the control peptide (Scale bars: 100 μm).